I think most of the stockholders on this board don't realize that when the deal does go through Gern stock price will go down. The stem cell programs have a dollar value and that is priced into the stock at the present time. When that asset is sold the stock price will adjust accordingly. The only hope is that the stock being given to gern holders will equal the amount of the drop in price. Since we haven't had any real shareholder value by this management it more than likely the drop will not equal the stock being distributed to gern stockholders.
If you look at BioTime's financial resources, it doesn't have enough money to go through the deal!! It has so many other things in its hands that, I believe, Okarma (now at BioTime) himself must come up with his plans to get the money to go for the deal!! And, that guy is not really that capable of doing that!! Of course, the Geron management must have been eager to close that deal. So, just wait and watch the drama that may unfold slowly and forget about that deal to be finalized with BioTime by September.